Biopharmaceutical company Gilead Sciences Inc (Nasdaq: GILD) on Monday reported real-world results from the BICSTaR study that reinforces the use of Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) as a generally well tolerated and efficacious regimen regardless of prior treatment and comorbidity status in people with HIV.
This latest five-year data from two Phase 3 studies (Study 1489 and Study 1490) provides evidence of the long-term safety and efficacy profile of Biktarvy in patients who switch from a dolutegravir-containing regimen.
Gilead presented new real-world data from the 24-month BICSTaR follow-up analysis which evaluated the effectiveness and safety of Biktarvy in clinical practice across nine countries. This analysis included follow-up during the COVID-19 pandemic and considered age, race, sex, adherence and late diagnosis in the population group.
The company stated that trial participants who initiated treatment with Biktarvy experienced high viral suppression (HIV-1 RNA
Thermo Fisher Scientific Launches CE-IVD Marked Assay to Detect Treatment-Resistant Strains of HIV-1
Gilead, EVOQ Therapeutics Team to Advance Immunotherapies
Clinical Microbiology Market to Reach USD 5.7bn by 2027, According to Research and Markets
AIDS Healthcare Foundation Calls on US to Fast-track COVID Tech Sharing
Infectious Disease Diagnostics Market to Reach USD 33.1bn by 2027, According to Research and Markets